ATE265846T1 - Butorphanol enthaltende formulierungen mit verzögerter freisetzung - Google Patents

Butorphanol enthaltende formulierungen mit verzögerter freisetzung

Info

Publication number
ATE265846T1
ATE265846T1 AT99936027T AT99936027T ATE265846T1 AT E265846 T1 ATE265846 T1 AT E265846T1 AT 99936027 T AT99936027 T AT 99936027T AT 99936027 T AT99936027 T AT 99936027T AT E265846 T1 ATE265846 T1 AT E265846T1
Authority
AT
Austria
Prior art keywords
sustained release
butorphanol
release formulations
formulations containing
formulations
Prior art date
Application number
AT99936027T
Other languages
English (en)
Inventor
Hung-Chih Chang
Lukchiu Li
Youqui Tian
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE265846T1 publication Critical patent/ATE265846T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99936027T 1998-02-25 1999-02-25 Butorphanol enthaltende formulierungen mit verzögerter freisetzung ATE265846T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3021798A 1998-02-25 1998-02-25
PCT/US1999/004113 WO1999043300A1 (en) 1998-02-25 1999-02-25 Butorphanol sustained release formulations

Publications (1)

Publication Number Publication Date
ATE265846T1 true ATE265846T1 (de) 2004-05-15

Family

ID=21853121

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99936027T ATE265846T1 (de) 1998-02-25 1999-02-25 Butorphanol enthaltende formulierungen mit verzögerter freisetzung

Country Status (8)

Country Link
US (1) US6197344B1 (de)
EP (1) EP1056443B1 (de)
JP (1) JP2002504505A (de)
AT (1) ATE265846T1 (de)
AU (1) AU753278B2 (de)
CA (1) CA2321924A1 (de)
DE (1) DE69917000T2 (de)
WO (1) WO1999043300A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6680067B2 (en) * 2001-11-26 2004-01-20 Oliver Yoa-Pu Hu Controlled-release pharmaceutical preparation containing nalbuphine and a process for preparing the same
AU2003225837B2 (en) * 2002-03-15 2008-11-06 Forest Laboratories Holdings Limited NE and 5-HT reuptake inhibitors for treating visceral pain syndromes
AU2003272601B2 (en) * 2002-09-20 2009-05-07 Alpharma Pharmaceuticals, Llc Sustained-release opioid formulations and methods of use
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
JP2006515008A (ja) * 2003-01-28 2006-05-18 コレギウム ファーマシューティカル， インコーポレイテッド 経口投与のためのミルナシプランの多粒子状組成物
US20080227805A1 (en) * 2007-02-28 2008-09-18 Abbott Laboratories Sustained release parenteral formulations of buprenorphine
EP2632441A4 (de) * 2010-10-29 2015-04-01 Relmada Therapeutics Inc Zusammensetzungen aus (-)-17-(cyclobutylmethyl-)morphinan-3,14-diol
AR101476A1 (es) 2014-08-07 2016-12-21 Acerta Pharma Bv Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
US11234974B2 (en) 2015-05-28 2022-02-01 Lumosa Therapeutics Co., Ltd. Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
US10183018B2 (en) 2015-05-28 2019-01-22 Lumosa Therapeutics Co., Ltd. Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
BR112017025395A2 (pt) 2015-05-28 2018-10-16 Lumosa Therapeutics Co Ltd formulações farmacêuticas para liberação prolongada de sebacoil éster de dinalbufina
CN111904928A (zh) * 2019-05-07 2020-11-10 江苏恒瑞医药股份有限公司 一种包含布托啡诺的可注射的药物组合物及其制备方法
CN116818928B (zh) * 2023-04-28 2024-04-19 杭州沐源生物医药科技有限公司 一种酒石酸布托啡诺注射液中杂质的分离检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE788478A (fr) 1971-09-08 1973-03-06 Bristol Myers Co Procede de preparation de composes analgesiques
CA1098444A (en) * 1975-05-26 1981-03-31 Leo Geller Peptide preparations with prolonged action
US4338324A (en) * 1981-03-17 1982-07-06 Mcneilab, Inc. Analgesic potentiation
US4322427A (en) 1981-04-16 1982-03-30 Bristol-Myers Company Analgetic compositions and methods of use
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
AU614527B2 (en) * 1987-07-24 1991-09-05 Nexstar Pharmaceuticals, Inc. Opioid analgesic liposomal delivery-release system
FR2663223B1 (fr) * 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
GB9226905D0 (en) * 1992-12-24 1993-02-17 Wellcome Found Pharmaceutical preparation
JP2596255Y2 (ja) 1993-03-23 1999-06-07 ナカミチ株式会社 ディスク再生装置
DE69603577T2 (de) 1995-02-10 1999-11-25 Medtronic, Inc. Verfahren und vorrichtung zur verabreichung von analgetika
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters

Also Published As

Publication number Publication date
EP1056443A1 (de) 2000-12-06
EP1056443B1 (de) 2004-05-06
DE69917000T2 (de) 2005-04-21
JP2002504505A (ja) 2002-02-12
US6197344B1 (en) 2001-03-06
AU3311299A (en) 1999-09-15
CA2321924A1 (en) 1999-09-02
DE69917000D1 (de) 2004-06-09
WO1999043300A1 (en) 1999-09-02
AU753278B2 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
ATE265846T1 (de) Butorphanol enthaltende formulierungen mit verzögerter freisetzung
RS50071B (sr) Novi oblik soli pantoprazola
ES2182234T3 (es) Inhibidores de metaloproteasa.
HN1998000057A (es) Derivados de nicotinamida
MXPA03010201A (es) Derivados de 2-piridin-ciclohexan-1,4-diamina sustituidos.
HRP20010573B1 (en) Tricyclic inhibitors of poly(adp-ribose) polymerases
ATE274348T1 (de) Überbrückte indenopyrrolocarbazole
MXPA02004556A (es) Soluciones que contienen epinastina.
PT1248867E (pt) Reducao electroquimica selectiva de acidos 4-aminopicolinicos halogenados
MXPA02009313A (es) Acilsulfimidas heterociclicas, un metodo para su produccion, agentes que contienen las mismas y su uso como plaguicidas.
IL138688A0 (en) Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme
AP2001002274A0 (en) Rescorcinol derivatives.
MY128164A (en) Compounds
BR0004524A (pt) Controle de odor em artigos absorventes
FR2815332B1 (fr) Devidoir suspendu, notamment pour cultures
ATE318825T1 (de) Herstellung von cephalosporin
BR0101437A (pt) Método para preparar um ciclopropeno
PA8524001A1 (es) Proceso para preparar 2-(4-piridil)amino-6-dialquiloxifenil-pirido (2,3-d) pirimidin-7-onas
PT1156999E (pt) Metodo para a preparacao de um beta-aminoester quiral
SE9602416D0 (sv) New forms of an organic salt of N'N-diacetylcystine
IL148234A0 (en) Composition for ivf
ITRM20010309A0 (it) Procedimento per la produzione di composti perfluoro-organici mediante florurazione elettrochimica.
MX9203486A (es) (quinolin-2-imetoxi)indol como inhibidores de la biosintesis de leucotrienos).
TR200102093T2 (tr) Organ koruyucu çözeltiler
PT1140932E (pt) Derivados de 1,8-benzonaftiridina

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties